Literature DB >> 32229721

Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer.

Ylia Salazar1, Xiang Zheng1, David Brunn1, Hartmann Raifer2,3, Felix Picard2, Yajuan Zhang2, Hauke Winter4, Stefan Guenther5, Andreas Weigert6, Benno Weigmann7, Laure Dumoutier8, Jean-Christophe Renauld8, Ari Waisman9, Anja Schmall1, Amanda Tufman10, Ludger Fink11, Bernhard Brüne6,12, Tobias Bopp13, Friedrich Grimminger14, Werner Seeger1,14,15, Soni Savai Pullamsetti1,14, Magdalena Huber2, Rajkumar Savai1,12,14,15.   

Abstract

Immune microenvironment plays a critical role in lung cancer control versus progression and metastasis. In this investigation, we explored the effect of tumor-infiltrating lymphocyte subpopulations on lung cancer biology by studying in vitro cocultures, in vivo mouse models, and human lung cancer tissue. Lymphocyte conditioned media (CM) induced epithelial-mesenchymal transition (EMT) and migration in both primary human lung cancer cells and cell lines. Correspondingly, major accumulation of Th9 and Th17 cells was detected in human lung cancer tissue and correlated with poor survival. Coculturing lung cancer cells with Th9/Th17 cells or exposing them to the respective CM induced EMT in cancer cells and modulated the expression profile of genes implicated in EMT and metastasis. These features were reproduced by the signatory cytokines IL-9 and IL-17, with gene regulatory profiles evoked by these cytokines partly overlapping and partly complementary. Coinjection of Th9/Th17 cells with tumor cells in WT, Rag1-/-, Il9r-/-, and Il17ra-/- mice altered tumor growth and metastasis. Accordingly, inhibition of IL-9 or IL-17 cytokines by neutralizing antibodies decreased EMT and slowed lung cancer progression and metastasis. In conclusion, Th9 and Th17 lymphocytes induce lung cancer cell EMT, thereby promoting migration and metastatic spreading and offering potentially novel therapeutic strategies.

Entities:  

Keywords:  Cancer; Inflammation; Oncology; T cells

Mesh:

Substances:

Year:  2020        PMID: 32229721      PMCID: PMC7324180          DOI: 10.1172/JCI124037

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition.

Authors:  Min Soon Cho; Rajesha Rupaimoole; Hyun-Jin Choi; Kyunghee Noh; Jichao Chen; Qianghua Hu; Anil K Sood; Vahid Afshar-Kharghan
Journal:  J Immunol       Date:  2015-12-30       Impact factor: 5.422

2.  Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer.

Authors:  Min-Chao Duan; Wei Han; Pei-Wen Jin; Yu-Ping Wei; Qiu Wei; Liang-Ming Zhang; Jun-Chen Li
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

3.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.

Authors:  Sergei I Grivennikov; Kepeng Wang; Daniel Mucida; C Andrew Stewart; Bernd Schnabl; Dominik Jauch; Koji Taniguchi; Guann-Yi Yu; Christoph H Osterreicher; Kenneth E Hung; Christian Datz; Ying Feng; Eric R Fearon; Mohamed Oukka; Lino Tessarollo; Vincenzo Coppola; Felix Yarovinsky; Hilde Cheroutre; Lars Eckmann; Giorgio Trinchieri; Michael Karin
Journal:  Nature       Date:  2012-11-08       Impact factor: 49.962

4.  IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis.

Authors:  Magdalena Huber; Sylvia Heink; Axel Pagenstecher; Katharina Reinhard; Josephine Ritter; Alexander Visekruna; Anna Guralnik; Nadine Bollig; Katharina Jeltsch; Christina Heinemann; Eva Wittmann; Thorsten Buch; Olivia Prazeres da Costa; Anne Brüstle; Dirk Brenner; Tak W Mak; Hans-Willi Mittrücker; Björn Tackenberg; Thomas Kamradt; Michael Lohoff
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

5.  Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression.

Authors:  P Pellegrini; A M Berghella; T Del Beato; S Cicia; D Adorno; C U Casciani
Journal:  Cancer Immunol Immunother       Date:  1996-01       Impact factor: 6.968

6.  IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells.

Authors:  Valérie Steenwinckel; Jamila Louahed; Ciriana Orabona; François Huaux; Guy Warnier; Andrew McKenzie; Dominique Lison; Roy Levitt; Jean-Christophe Renauld
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

7.  Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells.

Authors:  Rahul Purwar; Christoph Schlapbach; Sheng Xiao; Hong Soon Kang; Wassim Elyaman; Xiaodong Jiang; Anton M Jetten; Samia J Khoury; Robert C Fuhlbrigge; Vijay K Kuchroo; Rachael A Clark; Thomas S Kupper
Journal:  Nat Med       Date:  2012-07-08       Impact factor: 53.440

8.  Reciprocal regulation of the Il9 locus by counteracting activities of transcription factors IRF1 and IRF4.

Authors:  Lucia Campos Carrascosa; Matthias Klein; Yohko Kitagawa; Christina Lückel; Federico Marini; Anika König; Anna Guralnik; Hartmann Raifer; Stefanie Hagner-Benes; Diana Rädler; Andreas Böck; Cholho Kang; Michael Lohoff; Holger Garn; Bianca Schaub; Friederike Berberich-Siebelt; Shimon Sakaguchi; Tobias Bopp; Magdalena Huber
Journal:  Nat Commun       Date:  2017-05-12       Impact factor: 14.919

9.  The central role of CD4(+) T cells in the antitumor immune response.

Authors:  K Hung; R Hayashi; A Lafond-Walker; C Lowenstein; D Pardoll; H Levitsky
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

10.  Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.

Authors:  Xiao Lv; Lili Feng; Xueling Ge; Kang Lu; Xin Wang
Journal:  J Exp Clin Cancer Res       Date:  2016-07-01
View more
  36 in total

Review 1.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

2.  Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.

Authors:  Yinjie Gao; Michelle M Stein; Matthew Kase; Amy L Cummings; Ramit Bharanikumar; Denise Lau; Edward B Garon; Sandip P Patel
Journal:  Cancer Immunol Immunother       Date:  2022-07-26       Impact factor: 6.630

Review 3.  The Relationship between Cancer and Paraoxonase 1.

Authors:  Irma Martha Medina-Díaz; Néstor Ponce-Ruíz; Aurora Elizabeth Rojas-García; José Francisco Zambrano-Zargoza; Yael Y Bernal-Hernández; Cyndia Azucena González-Arias; Briscia S Barrón-Vivanco; José Francisco Herrera-Moreno
Journal:  Antioxidants (Basel)       Date:  2022-03-31

4.  Th9 and Th17 cells: the controversial twins in cancer immunity.

Authors:  Chi Yan; Ann Richmond
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

5.  CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer.

Authors:  Shaochuan Liu; Yuan Meng; Liang Liu; Yingge Lv; Wenwen Yu; Ting Liu; Limei Wang; Di Mu; Qiuru Zhou; Min Liu; Yulin Ren; Dong Zhang; Baihui Li; Qian Sun; Xiubao Ren
Journal:  Cell Death Dis       Date:  2022-05-06       Impact factor: 9.685

6.  Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules.

Authors:  Yasuyo Sano; Toshimi Yoshida; Min-Kyung Choo; Yanek Jiménez-Andrade; Kathryn R Hill; Katia Georgopoulos; Jin Mo Park
Journal:  Mol Cancer Res       Date:  2020-11-24       Impact factor: 6.333

Review 7.  Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy.

Authors:  Yin Qianmei; Su Zehong; Wang Guang; Li Hui; Gaojian Lian
Journal:  Immunol Res       Date:  2021-07-24       Impact factor: 2.829

Review 8.  Immunity beyond cancer cells: perspective from tumor tissue.

Authors:  Shengyu Gao; Ting-Wei Hsu; Ming O Li
Journal:  Trends Cancer       Date:  2021-07-22

9.  A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis.

Authors:  Tao Fan; Zhiliang Lu; Yu Liu; Liyu Wang; He Tian; Yujia Zheng; Bo Zheng; Liyan Xue; Fengwei Tan; Qi Xue; Shugeng Gao; Chunxiang Li; Jie He
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

10.  Tumor rejection in Cblb -/- mice depends on IL-9 and Th9 cells.

Authors:  Oliver Schanz; Isabelle Cornez; Sowmya Parampalli Yajnanarayana; Friederike Sophie David; Sebastian Peer; Thomas Gruber; Peter Krawitz; Peter Brossart; Annkristin Heine; Jenny Landsberg; Gottfried Baier; Dominik Wolf
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.